Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Atomera Incorporated (ATOM) vs Sana Biotechnology Inc (SANA) Price & Performance

Atomera IncorporatedTrade
Sana Biotechnology IncTrade

Price performance (Past 24H)

Key statistics

Atomera Incorporated vs Sana Biotechnology Inc — how do they compare? Atomera Incorporated trades at $5.57 (market cap $209.56M), while Sana Biotechnology Inc trades at $3.77 (market cap $1.01B). The key difference: Sana Biotechnology Inc is far larger — about 4.8× Atomera Incorporated's market cap. Which is the better fit depends on your goals.

ATOMSANA
Market Cap
$209.56M$1.01B
Sector
TechnologyHealth
52-Week High
$12.11$5.92
52-Week Low
$1.99$2.68
Enterprise Value
$172.37M$980.22M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Atomera Incorporated

ATOM trades at $5.48, up 3.1% today, but faces significant fundamental challenges with a P/S ratio of 797.66 and deeply negative profitability metrics including a -78.7% gross margin and -9,742% net income margin. The company has missed earnings expectations for three consecutive quarters while technical indicators show bearish momentum with RSI signaling overbought conditions at 78.05. Recent news highlights progress in semiconductor technology licensing but financial performance remains weak.

Despite unanimous analyst buy ratings, ATOM presents high-risk exposure due to substantial losses, negative cash flow, and elevated valuation multiples. The semiconductor licensing business shows technological promise but requires significant revenue acceleration to justify current valuation. Near-term catalysts depend on commercial adoption breakthroughs while downside risk remains elevated given current financial metrics.

Sana Biotechnology Inc

SANA Biotechnology trades at $3.52, up 3.23% with a bullish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn improved in 2026. Recent positive developments include clinical data presentations and a $69M stock offering. Analyst consensus remains strong with 82% buy ratings and a $9.50 price target.

While SANA shows promising clinical progress and strong analyst support, significant financial losses and cash burn present substantial risks. The stock's upside potential depends on successful clinical trial outcomes and path to profitability, making it suitable for risk-tolerant investors seeking biotech exposure.

Returns comparison

Trailing returns across standard periods

About Atomera Incorporated

Atomera is a semiconductor materials engineering company. Its Mears Silicon Technology (MST) is a patented thin film that enhances transistor performance, power efficiency, and cost for global chip manufacturers.

Read more on ATOM

About Sana Biotechnology Inc

Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.

Read more on SANA